Literature DB >> 16608506

The results of imatinib therapy for patients with primary eosinophilic disorders.

Grzegorz Helbig, Beata Stella-Holowiecka, Sebastian Grosicki, Grazyna Bober, Magorzata Krawczyk, Jerzy Wojnar, Andreas Reiter, Andreas Hochhaus, Jerzy Holowiecki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16608506     DOI： 10.1111/j.1600-0609.2006.00652.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  8 in total

Review 1.  Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond.

Authors:  Siba El Hussein; Joseph D Khoury; L Jeffrey Medeiros; Sanam Loghavi
Journal:  Curr Hematol Malig Rep       Date:  2021-05-04       Impact factor: 3.952

Review 2.  Recent Updates on Chronic Myelomonocytic Leukemia.

Authors:  Sanam Loghavi; Joseph D Khoury
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 3.  Chronic Myelomonocytic Leukemia: Hematopathology Perspective.

Authors:  Siba El Hussein; Sa A Wang; Naveen Pemmaraju; Joseph D Khoury; Sanam Loghavi
Journal:  J Immunother Precis Oncol       Date:  2021-06-18

4.  Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

Authors:  Nitin Jain; Jorge Cortes; Alfonso Quintás-Cardama; Taghi Manshouri; Raja Luthra; Guillermo Garcia-Manero; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2008-11-14       Impact factor: 3.156

5.  Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.

Authors:  Grzegorz Helbig; Andrzej Moskwa; Marek Hus; Jarosław Piszcz; Alina Swiderska; Alina Urbanowicz; Małgorzata Całbecka; Ilona Seferyńska; Małgorzata Raźny; Marek Rodzaj; Ewa Żuk; Sławomira Kyrcz-Krzemień
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-17       Impact factor: 3.333

6.  FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia.

Authors:  Gedeon Loules; Fani Kalala; Nikolaos Giannakoulas; Emmanouil Papadakis; Panagiota Matsouka; Matthaios Speletas
Journal:  BMC Blood Disord       Date:  2009-02-02

7.  Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Jose A Cancelas
Journal:  Transl Oncogenomics       Date:  2006-12-05

8.  Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.

Authors:  Shilpan Shah; Sanam Loghavi; Guillermo Garcia-Manero; Joseph D Khoury
Journal:  J Hematol Oncol       Date:  2014-03-27       Impact factor: 17.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.